ACG clinical guideline: Diagnosis, treatment, and prevention of acute diarrheal infections in adults

American Journal of Gastroenterology

Volumn 111, Issue 5, 2016, Pages 602-622

  Riddle, Mark S ^a   Dupont, Herbert L ^b   Connor, Bradley A ^c  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETORPHAN; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZITHROMYCIN; BISMUTH SALICYLATE; CIPROFLOXACIN; CROFELEMER; DIPHENOXYLATE; LEVOFLOXACIN; LOPERAMIDE; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; SYNBIOTIC AGENT; ZALDARIDE MALEATE;

ACUTE DIARRHEA; ACUTE DIARRHEA INFECTION; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; CHRONIC DIARRHEA; CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ELECTRON MICROSCOPY; ENTAMOEBA DISPAR; ENTAMOEBA HISTOLYTICA; ENTEROCOCCUS; ESCHERICHIA COLI; EVIDENCE BASED PRACTICE; FECES ANALYSIS; FECES CULTURE; FEVER; FOOD POISONING; FOOD SAFETY; GIARDIASIS; HAND WASHING; HUMAN; IMMUNOFLUORESCENCE; INCONTINENCE; INFECTION CONTROL; INFECTIOUS DIARRHEA; IRRITABLE COLON; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; MICROBIAL IDENTIFICATION; MICROSCOPY; NAUSEA; NONHUMAN; ORAL REHYDRATION THERAPY; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW (TOPIC); TRAVELLER DIARRHEA; VOMITING; WEIGHT REDUCTION; ACUTE DISEASE; ADULT; ALGORITHM; DIARRHEA; UNITED STATES;

ACUTE DISEASE; ADULT; ALGORITHMS; DIARRHEA; HUMANS; UNITED STATES;

EID: 84963556370     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.126     Document Type: Review

References (248)

1. Scallan E, Griffin PM, Angulo FJ, et al. Foodborne illness acquired in the United States-unspecified agents. Emerg Infect Dis 2011; 17: 16-22
2. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011; 17: 7-15
3. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-98. quiz 499
4. DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997; 92: 1962-75
5. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice Guidelines for the Management of Infectious Diarrhea. Clin Infect Dis 2001; 32: 331-51
6. Farthing M, Salam MA, Lindberg G, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol 2013; 47: 12-20
7. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases.Infectious Diseases Society of America. Clin Infect Dis 1994; 18: 421
8. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490
9. Imhoff B, Morse D, Shiferaw B, et al. Burden of self-reported acute diarrheal illness in FoodNet surveillance areas, 1998-1999. Clin Infect Dis 2004; 38: Suppl 3 S219-S226
10. Cantwell LB, Henao OL, Hoekstra RM, et al. The Effect of diff erent recall periods on estimates of acute gastroenteritis in the United States, FoodNet Population Survey 2006-2007. Foodborne Pathog Dis 2010; 7: 1225-8
11. Roy SL, Scallan E, Beach MJ. The rate of acute gastrointestinal illness in developed countries. J Water Health 2006; 4: Suppl 2 31-69
12. US Department of Commerce. 2014 US Travel and Tourism Statistics (US Resident Outbound), Monthly US Outbound Air Travel to International Regions. Available at: http://travel.trade.gov/view/m-2014-O-001/14outbound.xls, National Travel and Tourism Offi ce (NTTO); 2014 last accesed 1 March 2015
13. Steffen R, Hill DR, DuPont HL. Traveler?s diarrhea: a clinical review. JAMA 2015; 313: 71-80
14. Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology 2010; 138: 1727-36. quiz e12
15. Mearin F. Postinfectious functional gastrointestinal disorders. J Clin Gastroenterol 2011; 45: S102-S105
16. Mearin F, Perello A, Balboa A, et al. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol 2009; 44: 1173-85
17. Porter CK, Gloor K, Cash BD, et al. Risk of functional gastrointestinal disorders in U.S. military following self-reported diarrhea and vomiting during deployment. Dig Dis Sci 2011; 56: 3262-9
18. Porter CK, Gormley R, Tribble DR, et al. The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 2011; 106: 130-8
19. Tuteja AK, Talley NJ, Gelman SS, et al. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. Dig Dis Sci 2008; 53: 271-6
20. Raja MK, Ghosh AR. L aribacter hongkongensis: an emerging pathogen of infectious diarrhea. Folia Microbiol 2014; 59: 341-7
21. Hoffmann S, Batz MB, Morris JG Jr. Annual cost of illness and qualityadjusted life year losses in the United States due to 14 foodborne pathogens. J Food Prot 2012; 75: 1292-302
22. Scharff RL. Economic burden from health losses due to foodborne illness in the United States. J Food Prot 2012; 75: 123-31
23. Minor T, Lasher A, Klontz K, et al. The per case and total annual costs of foodborne illness in the United States. Risk Anal 2015; 35: 1125-39
24. Braden CR, Tauxe RV. Emerging trends in foodborne diseases. Infect Dis Clin N Am 2013; 27: 517-33
25. Glass K, Ford L, Kirk MD. Drivers of uncertainty in estimates of foodborne gastroenteritis incidence. Foodborne Pathog Dis 2014; 11: 938-44
26. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis 2013; 57: Suppl 3 S139-S170
27. Jones TF, Scallan E, Angulo FJ. FoodNet: overview of a decade of achievement. Foodborne Pathog Dis 2007; 4: 60-6
28. Donnenberg MS, Narayanan S. How to diagnose a foodborne illness. Infect Dis Clin N Am 2013; 27: 535-54
29. DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for self-therapy of travelers? Diarrhea. J Travel Med 2009; 16: 161-71
30. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers? Diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 2009; 80: 6 09- 1 4
31. Mattila L. Clinical features and duration of traveler?s diarrhea in relation to its etiology. Clin Infect Dis 1994; 19: 728-34
32. Humphries RM, Linscott AJ. Laboratory diagnosis of bacterial gastroenteritis. Clin Microbiol Rev 2015; 28: 3-31
33. Lee HM, Lee S, Lee BI, et al. Clinical signifi cance of fecal lactoferrin and multiplex polymerase chain reaction in patients with acute diarrhea. Gut Liver 2014; 23: 636-40
34. Libman MD, Gyorkos TW, Kokoskin E, et al. Detection of pathogenic protozoa in the diagnostic laboratory: result reproducibility, specimen pooling, and competency assessment. J Clin Microbiol 2008; 46: 2200-5
35. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009; 361: 1776-85
36. Raich TJ, Powell S. The changing landscape of diagnostic testing for diarrheal disease. Med Lab Obs 2014; 46: 36-38
37. Dunbar SA. Molecular revolution entering GI diagnostic testing. Med Lab Obs 2013; 45: 28
38. Goldenberg SD, Bacelar M, Brazier P, et al. A cost benefit analysis of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalised patients. J Infect 2015; 70: 504-11
39. Drancourt M. Multiplex testing of diarrhoea breaks down microbial barriers. Lancet Infect Dis 2014; 14: 663-4
40. Beckmann C, Heininger U, Marti H, et al. Gastrointestinal pathogens detected by multiplex nucleic acid amplifi cation testing in stools of pediatric patients and patients returning from the tropics. Infection 2014; 42: 961-70
41. Halligan E, Edgeworth J, Bisnauthsing K, et al. Multiplex molecular testing for management of infectious gastroenteritis in a hospital setting: a comparative diagnostic and clinical utility study. Clin Microbiol Infect 2014; 20: O460-O467
42. Cheun HI, Chung BS, Ma DW, et al. Development of a diagnostic kit to detect Cryptosporidium parvum and Giardia lamblia. Osong Public Health Res Perspect 2013; 4: 146-51
43. Saigal K, Khurana S, Sharma A, et al. Comparison of staining techniques and multiplex nested PCR for diagnosis of intestinal microsporidiosis. Diagn Microbiol Infect Dis 2013; 77: 248-9
44. Antikainen J, Kantele A, Pakkanen SH, et al. A quantitative polymerase chain reaction assay for rapid detection of 9 pathogens directly from stools of travelers with diarrhea. Clin Gastroenterol Hepatol 2013; 11: 1300-7. e3
45. McAuliff e GN, Anderson TP, Stevens M, et al. Systematic application of multiplex PCR enhances the detection of bacteria, parasites, and viruses in stool samples. J Infect 2013; 67: 122-9
46. Liu J, Kibiki G, Maro V, et al. Multiplex reverse transcription PCR Luminex assay for detection and quantitation of viral agents of gastroenteritis. J Clin Virol 2011; 50: 308-13
47. Buchan BW, Olson WJ, Pezewski M, et al. Clinical evaluation of a realtime PCR assay for Identification of Salmonella, Shigella, Campylobacter (Campylobacter jejuni and C. coli ), and shiga toxin-producing Escherichia coli isolates in stool specimens. J Clin Microbiol 2013; 51: 4001-7
48. Gray J, Coupland LJ. The increasing application of multiplex nucleic acid detection tests to the diagnosis of syndromic infections. Epidemiol Infect 2014; 142: 1-11
49. Liu Y, Xu ZQ, Zhang Q, et al. Simultaneous detection of seven enteric viruses associated with acute gastroenteritis by a multiplexed Luminexbased assay. J Clin Microbiol 2012; 50: 2384-9
50. Platts-Mills JA, Operario DJ, Houpt ER. Molecular diagnosis of diarrhea: current status and future potential. Curr Infect Dis Rep 2012; 14: 41-6
51. Platts-Mills JA, Liu J, Houpt ER. New concepts in diagnostics for infectious diarrhea. Mucosal Immunol 2013; 6: 876-85
52. Van Lint P, De Witte E, De Henau H, et al. Evaluation of a real-time multiplex PCR for the simultaneous detection of Campylobacter jejuni, Salmonella spp ., Shigella spp ./EIEC, and Yersinia enterocolitica in fecal samples. Eur J Clin Microbiol Infect Dis 2015; 34: 535-42
53. Verkerke HP, Sobuz SU, Petri WA Jr. Molecular diagnosis of infectious diarrhea: focus on enteric protozoa. Expert Rev Mol Diagn 2014; 14: 935-46
54. Yansouni CP, Merckx J, Libman MD, et al. Recent advances in clinical parasitology diagnostics. Curr Infect Dis Rep 2014; 16: 434
55. Gaudreau C, Barkati S, Leduc JM, et al. S higella spp. with reduced azithromycin susceptibility, Quebec, Canada, 2012-2013. Emerg Infect Dis 2014; 20: 854-6
56. Peleg I, Givon-Lavi N, Leibovitz E, et al. Epidemiological trends and patterns of antimicrobial resistance of Shigell a spp. isolated from stool cultures in two diff erent populations in Southern Israel. Diagn Microbiol Infect Dis 2014; 78: 287-91
57. Zhang J, Jin H, Hu J, et al. Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2004-2011. Diagn Microbiol Infect Dis 2014; 78: 282-6
58. Mandal J, Sangeetha V, Nivedithadivya D, et al. Characterization of extended-spectrum ß -lactamase-producing clinical isolates of Shigella fl exneri. J Health Popul Nutr 2013; 31: 405-8
59. Pons MJ, Gomes C, Martinez-Puchol S, et al. Antimicrobial resistance in Shigella spp. causing traveller?s diarrhoea (1995-2010): a retrospective analysis. Travel Med Infect Dis 2013; 11: 315-9
60. Kansakar P, Baral P, Malla S, et al. Antimicrobial susceptibilities of enteric bacterial pathogens isolated in Kathmandu, Nepal, during 2002-2004. J Infect Dev Ctries 2011; 5: 163-8
61. Howie RL, Folster JP, Bowen A, et al. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb Drug Resist 2010; 16: 245-8
62. Wong MR, Reddy V, Hanson H, et al. Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009. Microb Drug Resist 2010; 16: 155-61
63. Cronquist AB, Mody RK, Atkinson R, et al. Impacts of culture-independent diagnostic practices on public health surveillance for bacterial enteric pathogens. Clin Infect Dis 2012; 54: Suppl 5 S432-S439
64. Maragkoudakis S, Poulidaki SR, Papadomanolaki E, et al. Empiric antimicrobial therapy and infectious diarrhea. Do we need local guidelines? Eur J Intern Med 2011; 22: e60-e62
65. Sjolund Karlsson M, Bowen A, Reporter R, et al. Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States. Antimicrob Agents Chemother 2013; 57: 1559-60
66. Victora CG, Bryce J, Fontaine O, et al. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ 2000; 78: 1246-55
67. Gangarosa RE, Glass RI, Lew JF, et al. Hospitalizations involving gastroenteritis in the United States, 1985: the special burden of the disease among the elderly. Am J Epidemiol 1992; 135: 281-90
68. Caeiro JP, DuPont HL, Albrecht H, et al. Oral rehydration therapy plus loperamide versus loperamide alone in the treatment of traveler?s diarrhea. Clin Infect Dis 1999; 28: 1286-9
69. Casburn-Jones AC, Farthing MJ. Management of infectious diarrhoea. Gut 2004; 53: 296-305
70. Snyder JD, Molla AM, Cash RA. Home-based therapy for diarrhea. J Pediatr Gastroenterol Nutr 1990; 11: 438-47
71. Wendland BE, Arbus GS. Oral fluid therapy: sodium and potassium content and osmolality of some commercial clear soups, juices and beverages. Can Med Assoc J 1979; 121: 564-6. 568, 571
72. Duggan C, Fontaine O, Pierce NF, et al. Scientific rationale for a change in the composition of oral rehydration solution. JAMA 2004; 291: 2628-31
73. Baker LB, Jeukendrup AE. Optimal composition of fluid-replacement beverages. Compr Physiol 2014; 4: 575-620
74. Binder HJ, Brown I, Ramakrishna BS, et al. Oral rehydration therapy in the second decade of the twenty-first century. Curr Gastroenterol Rep 2014; 16: 376
75. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000; 71: 1682S-1687S. discussion 1688S-90S
76. Dunne C, O?Mahoney L, Murphy L. I n vitro selection criteria for propbiotic bacteria of human origin: correlation with in vivo fi ndings. Am J Clin Nutr 2001; 73: 3865-925
77. FAO/WHO. Joint FAO/WHO Working Group Report on Draft ing Guidelines for the Evaluation of Probiotics in Food WHO: Geneva, Switzerland, 2002
78. Gibson GR, Probert HM, Loo JV, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004; 17: 259-75
79. Tojo M, Oikawa T, Morikawa Y, et al. The Effects of Bifi dobacterium breve administration on Campylobacter enteritis. Acta Pediatr Jpn 2007; 29: 160-7
80. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifi dobacterium bifi dum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344: 1046-9
81. Nemcova R, Bomba A, Gancarcinova S, et al. Effects of the administration of lactobacilli, maltodextrins and fructooligosaccharides upon the adhesion of E-Coli O8: K88 to the intestinal mucosa and organic acid levels in the gut contents of piglets. Vet Res Commun 2007; 31: 791-800
82. Power SE, O?Toole PW, Stanton C, et al. Intestinal microbiota, diet and health. Br J Nutr 2014; 111: 387-402
83. Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010, CD003048
84. Bruno F, Frigerio G. A new therapeutic alternative for the treatment of enteritis-controlled double-blind tests with the strain SF 68]. Schweiz Rundsch Med Prax 1981; 70: 1717-20
85. Bruno F, Nastasi A, Bruno M. Double-blind controlled study of the Effect of the lactogenic enterococcus SF68 strain on various enterocolitis associated manifestations and on salmonella infections. Clin Ter 1983; 105: 203-7
86. Buydens P, Debeuckelaere S. Efficacy of SF 68 in the treatment of acute diarrhea. A placebo-controlled trial. Scand J Gastroenterol 1996; 31: 887-91
87. Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the Efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res 1989; 17: 333-8
88. Mitra AK, Rabbani GH. A double-blind, controlled trial of biofl orin (Streptococcus faecium SF68) in adults with acute diarrhea due to Vibrio cholerae and enterotoxigenic Escherichia coli. Gastroenterology 1990; 99: 1149-52
89. Höchter W, Chase D, Hagenhoff G. Saccharomyces boulardii in the treatment of acute adult diarrhoea. [Saccharomyces boulardii bei acuter Erwachsenendiarrhoea]. Münchener medizinische Wochenschrift 1990; 132: 188-92
90. Lund B, Edlund C. Probiotic Enterococcus faecium strain is a possible recipient of the vanA gene cluster. Clin Infect Dis 2001; 32: 1384-5
91. Szajewska H, Guarino A, Hojsak I, et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 2014; 58: 531-9
92. Noguera T, Wotring R, Melville CR, et al. Resolution of acute gastroenteritis symptoms in children and adults treated with a novel polyphenol-based prebiotic. World J Gastroenterol 2014; 20: 12301-7
93. Souza DN, Jorge MT. The Effect of Lactobacillus casei and Bifi dobacterium breve on antibiotic-associated diarrhea treatment: randomized doubleblind clinical trial. Rev Soc Bras Med Trop 2012; 45: 112-6
94. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307: 1959-69
95. DuPont HL, Sullivan P, Pickering LK, et al. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology 1977; 73: 715-8
96. DuPont HL, Ericsson CD, Mathewson JJ, et al. Zaldaride maleate, an intestinal calmodulin inhibitor, in the therapy of travelers? Diarrhea. Gastroenterology 1993; 104: 709-15
97. DiCesare D, DuPont HL, Mathewson JJ, et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol 2002; 97: 2585-8
98. DuPont HL. Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm 1987; 21: 687-93
99. Macarthur RD, Hawkins TN, Brown SJ, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials 2013; 14: 261-73
100. Shook JE, Burks TF, Wasley JW, et al. Novel calmodulin antagonist CGS 9343B inhibits secretory diarrhea. J Pharmacol Exp Ther 1989; 251: 247-52
101. Okhuysen PC, DuPont HL, Ericsson CD, et al. Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler?s diarrhea: randomized, placebo-controlled trial. Clin Infect Dis 1995; 21: 341-4
102. Siberschmidt G, Schick MT, Steffen R, et al. Treatment of travellers? Diarrhoea: zaldaride compared with loperamide and placebo. Eur J Gastro enterol Hep 1995; 7: 871-5
103. Primi MP, Bueno L, Baumer P, et al. Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment Pharmacol Ther 1999; 13 Suppl 6: 3-7
104. Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, et al. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000; 343: 463-7
105. Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J Gastroenterol 2005; 11: 1540-3
106. Schiller LR, Santa Ana CA, Morawski SG, et al. Mechanism of the antidiarrheal Effect of loperamide. Gastroenterology 1984; 86: 1475-80
107. Stoll R, Ruppin H, Domschke W. Calmodulin-mediated Effects of loperamide on chloride transport by brush border membrane vesicles from human ileum. Gastroenterology 1988; 95: 69-76
108. Johnson PC, Ericsson CD, DuPont HL, et al. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers? Diarrhea. JAMA 1986; 255: 757-60
109. Kaplan MA, Prior MJ, McKonly KI, et al. A multicenter randomized controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhea in children. Clin Pediatr (Phila) 1999; 38: 579-91
110. Hanauer SB, DuPont HL, Cooper KM, et al. Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin 2007; 23: 1033-43
111. Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler?s diarrhea: a systematic review and meta-analysis. Clin Infect Dis 2008; 47: 1007-14
112. DuPont HL, Hornick RB. Adverse Effect of lomotil therapy in shigellosis. JAMA 1973; 226: 1525-8
113. Koo HL, Koo DC, Musher DM, et al. A ntimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48: 598-605
114. DuPont HL, Ericsson CD, DuPont MW, et al. A randomized, open-label comparison of nonprescription loperamide and attapulgite in the symptomatic treatment of acute diarrhea. Am J Med 1990; 88: 20S-23S
115. Portnoy BL, DuPont HL, Pruitt D, et al. Antidiarrheal agents in the treatment of acute diarrhea in children. JAMA 1976; 236: 844-6
116. De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travellers? Diarrhoea. Cochrane Database Syst Rev 2000; 3: CD002242
117. Dupont HL, Cooperstock M. Cmea evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Clin Infect Dis 1992; 15: S228-S235
118. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofl oxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003; 37: 1165-71
119. Ericsson CD, Johnson PC, Dupont HL, et al. Ciprofl oxacin or trimethoprimsulfamethoxazole as initial therapy for travelers diarrhea - A placebocontrolled, randomized trial. Ann Intern Med 1987; 106: 216-20
120. Ericsson CD, DuPont HL, Mathewson JJ. Optimal dosing of ofl oxacin with loperamide in the treatment of non-dysenteric travelers? Diarrhea. J Travel Med 2001; 8: 207-9
121. Salam I, Katelaris P, Leigh-Smith S, et al. Randomised trial of single-dose ciprofl oxacin for travellers? Diarrhoea. Lancet 1994; 344: 1537-9
122. Mattila L, Peltola H, Siitonen A, et al. Short-term treatment of traveler?s diarrhea with norfl oxacin: a double-blind, placebo-controlled study during two seasons. Clin Infect Dis 1993; 17: 779-82
123. EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2013. The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2011. EFSA J 2013; 11: 3196-555
124. Ruiz J, Marco F, Oliveira I, et al. Trends in antimicrobial resistance in Campylobacter spp. causing traveler?s diarrhea. APMIS 2007; 115: 218-24
125. Bennish ML, Salam MA, Khan WA, et al. Treatment of shigellosis: III. Comparison of one-or two-dose ciprofl oxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 1992; 117: 727-34
126. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341-5
127. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter Enteritis in travelers to Thailand, an area where ciprofl oxacin resistance is prevalent. Clin Infect Dis 1995; 21: 536-41
128. Wistrom JJM, Hedstrom S, Alesig K, et al. Short-term self-treatment of travellers? Diarrhea with norfl oxacin: a placebo-controlled study. J Antimicrob Chemother 1989; 23: 905-13
129. Dupont HL, Ericsson C, Mathewson J, et al. Five versus three daysof ofl oxacin therapy for traveler?s diarrhea: a placebo-controlled study. Antimicrob Agents Chemother 1992; 36: 87-91
130. Wistrom JGL, Palmgren A, Price M, et al. Ecological Effects of short term ciprofl oxacin treatment of travelers? Diarrheoa. J Antimicrob Chemother 1992; 30: 693-706
131. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, doubleblind, multicenter study of rifaximin compared with placebo and with ciprofl oxacin in the treatment of travelers? Diarrhea. Am J Trop Med Hyg 2006; 74: 1060-6
132. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fl uoroquinolones as the predominant risk factor for Clostridium difficile -associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60
133. Shiferaw B, Solghan S, Palmer A, et al. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010. Clin Infect Dis 2012; 54: Suppl 5 S458-S463
134. Christopher PR, David KV, John SM, et al. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010, CD006784
135. Sanders JW, Frenck RW, Putnam SD, et al. Azithromycin and loperamide are comparable to levofl oxacin and loperamide for the treatment of traveler?s diarrhea in United States military personnel in Turkey. Clin Infect Dis 2007; 45: 294-301
136. Tribble DR, Sanders JW, Pang LW, et al. Traveler?s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofl oxacin regimen. Clin Infect Dis 2007; 44: 338-46
137. Gomi H, Jiang ZD, Adachi JA, et al. I n vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler?s diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45: 212-6
138. Khan IA, Schwartzman JD, Matsuura T, et al. A dichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice. Proc Natl Acad Sci USA 1997; 94: 13955-60
139. Ouyang-Latimer J, Jafri S, VanTassel A, et al. I n vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother 2011; 55: 874-8
140. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofl oxacin for the treatment of traveler?s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33: 1807-15
141. Infante RM, Ericsson CD, Jiang ZD, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004; 2: 135-8
142. Dupont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofl oxacin for the treatment of travelers? Diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33: 1807-15
143. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers? Diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98: 1073-8
144. Safdar N, Said A, Gangnon RE, et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 enteritis: a metaanalysis. JAMA 2002; 288: 996-1001
145. Musher DM, Rubenstein AD. Permanent carriers of nontyphosa salmonellae. Arch Intern Med 1973; 132: 869-72
146. Norman FF, Perez-Molina J, Perez de Ayala A, et al. Clostridium difficile -associated diarrhea after antibiotic treatment for traveler?s diarrhea. Clin Infect Dis 2008; 46: 1060-3
147. Kantele A, Laaveri T, Mero S, et al. Antimicrobials increase travelers? risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae. Clin Infect Dis 2015; 60: 837-46
148. Connor BA, Keystone JS. Antibiotic self-treatment of travelers? Diarrhea: helpful or harmful? Clin Infect Dis 2015; 60: 847-8
149. Granados CE, Reveiz L, Uribe LG, et al. Drugs for treating giardiasis. Cochrane Database Syst Rev 2012; 12: CD007787
150. Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, et al. A metaanalysis of the Effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis 2010; 4: e682
151. Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med 2003; 348: 1565-73
152. Mackey-Lawrence NM, Petri WA Jr. Amoebic dysentery. BMJ Clin Evid 2011; 2011
153. Bobak DA. Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond. Curr Infect Dis Rep 2006; 8: 91-5
154. Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005; 27: 1859-84
155. Ortega YR, Sanchez R. Update on Cyclospora cayetanensis, a food-borne and waterborne parasite. Clin Microbiol Rev 2010; 23: 218-34
156. Connor BA. Chronic diarrhea in travelers. Curr Infect Dis Rep 2013; 15: 203-10
157. Hines J, Nachamkin I. Effective use of the clinical microbiology laboratory for diagnosing diarrheal diseases. Clin Infect Dis 1996; 23: 1292-301
158. Operario DJ, Houpt E. Defi ning the causes of diarrhea: novel approaches. Curr Opin Infect Dis 2011; 24: 464-71
159. Fujioka M, Kasai K, Miura T, et al. Rapid diagnostic method for the detection of diarrheagenic Escherichia coli by multiplex PCR. Jpn J Infect Dis 2009; 62: 476-80
160. Couturier MR, Lee B, Zelyas N, et al. Shiga-toxigenic Escherichia coli detection in stool samples screened for viral gastroenteritis in Alberta, Canada. J Clin Microbiol 2011; 49: 574-8
161. Wolk DM, Schneider SK, Wengenack NL, et al. Real-time PCR method for detection of encephalitozoonintestinalis from stool specimens. J Clin Microbiol 2002; 40: 3922-8
162. Amar CF, East C, Maclure E, et al. Blinded application of microscopy, bacteriological culture, immunoassays and PCR to detect gastrointestinal pathogens from faecal samples of patients with community-acquired diarrhoea. Eur J Clin Microbiol Infect Dis 2004; 23: 529-34
163. Wahnschaff e U, Ignatius R, Loddenkemper C, et al. Diagnostic value of endoscopy for the diagnosis of giardiasis and other intestinal diseases in patients with persistent diarrhea from tropical or subtropical areas. Scand J Gastroenterol 2007; 42: 391-6
164. Marshall JB, Singh R, Diaz-Arias AA. Chronic, unexplained diarrhea: are biopsies necessary if colonoscopy is normal? Am J Gastroenterol 1995; 90: 372-6
165. Patel Y, Pettigrew NM, Grahame GR, et al. The diagnostic yield of lower endoscopy plus biopsy in nonbloody diarrhea. Gastrointest Endosc 1997; 46: 338-43
166. Lee JH, Rhee PL, Kim JJ, et al. The role of mucosal biopsy in the diagnosis of chronic diarrhea: value of multiple biopsies when colonoscopic fi nding is normal or nonspecific. Korean J Intern Med 1997; 12: 182-7
167. Shah RJ, Fenoglio-Preiser C, Bleau BL, et al. Usefulness of colonoscopy with biopsy in the evaluation of patients with chronic diarrhea. Am J Gastroenterol 2001; 96: 1091-5
168. Fine KD, Seidel RH, Do K. The prevalence, anatomic distribution, and diagnosis of colonic causes of chronic diarrhea. Gastrointest Endosc 2000; 51: 318-26
169. da Silva JG, De Brito T, Cintra Damiao AO, et al. Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic fi ndings. J Clin Gastroenterol 2006; 40: 44-8
170. Committee ASoP. Shen B, Khan K, et al. The role of endoscopy in the management of patients with diarrhea. Gastrointest Endosc 2010; 71: 887-92
171. Shale MJ, Walters JR, Westaby D. Adequacy of fl exible sigmoidoscopy with biopsy for diarrhea in patients under age 50 without features of proximal disease. Gastrointest Endosc 2011; 73: 757-64
172. Schussele Filliettaz S, Juillerat P, Burnand B, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known Inflammatory bowel disease. Endoscopy 2009; 41: 218-26
173. Adler A, Roll S, Marowski B, et al. Appropriateness of colonoscopy in the era of colorectal cancer screening: a prospective, multicenter study in a private-practice setting (Berlin Colonoscopy Project 1, BECOP 1). Dis Colon Rectum 2007; 50: 1628-38
174. Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci 2002; 47: 1122-8
175. de Bosset V, Froehlich F, Rey JP, et al. Do explicit appropriateness criteria enhance the diagnostic yield of colonoscopy? Endoscopy 2002; 34: 360-8
176. Duncan JE, Sweeney WB, Trudel JL, et al. Colonoscopy in the elderly: low risk, low yield in asymptomatic patients. Dis Colon Rectum 2006; 49: 646-51
177. Fernandez-Banares F, Salas A, Forne M, et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol 1999; 94: 418-23
178. Gonvers JJ, Harris JK, Wietlisbach V, et al. A European view of diagnostic yield and appropriateness of colonoscopy. Hepatogastroenterology 2007; 54: 729-35
179. Lasson A, Kilander A, Stotzer PO. Diagnostic yield of colonoscopy based on symptoms. Scand J Gastroenterol 2008; 43: 356-62
180. Lieberman DA, de Garmo PL, Fleischer DE, et al. Colonic neoplasia in patients with nonspecific GI symptoms. Gastrointest Endosc 2000; 51: 647-51
181. Matteoni CA, Wang N, Goldblum JR, et al. Flexible sigmoidoscopy for the detection of microscopic colitis. Am J Med 2000; 108: 416-8
182. Morini S, Hassan C, Meucci G, et al. Diagnostic yield of open access colonoscopy according to appropriateness. Gastrointest Endosc 2001; 54: 175-9
183. Offner FA, Jao RV, Lewin KJ, et al. Collagenous colitis: a study of the distribution of morphological abnormalities and their histological detection. Hum Pathol 1999; 30: 451-7
184. Olesen M, Eriksson S, Bohr J, et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004; 53: 346-50
185. Pardi DS, Loftus EV Jr., Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut 2007; 56: 504-8
186. Yusoff IF, Ormonde DG, Hoffman NE. Routine colonic mucosal biopsy and ileoscopy increases diagnostic yield in patients undergoing colonoscopy for diarrhea. J Gastroenterol Hepatol 2002; 17: 276-80
187. Connor BA. Sequelae of traveler?s diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005; 41: Suppl 8 S577-S586
188. Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler?s diarrhea. Clin Infect Dis 2005; 41: Suppl 8 S531-S535
189. Tafuri S, Guerra R, Gallone MS, et al. Effectiveness of pre-travel consultation in the prevention of travel-related diseases: a retrospective cohort study. Travel Med Infect Dis 2014; 12: 745-9
190. Wikswo ME, Hall AJ, et al. Centers for Disease C. Outbreaks of acute gastroenteritis transmitted by person-to-person contact-United States, 2009-2010. MMWR Surveill Summ 2012; 61: 1-12
191. DuPont HL. Acute infectious diarrhea in immunocompetent adults. N Engl J Med 2014; 370: 1532-40
192. DuPont HL, Formal SB, Hornick RB, et al. Pathogenesis of Escherichia coli diarrhea. N Engl J Med 1971; 285: 1-9
193. Nataro JP, Deng Y, Cookson S, et al. Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis 1995; 171: 465-8
194. Steinmann J, Paulmann D, Becker B, et al. Comparison of virucidal activity of alcohol-based hand sanitizers versus antimicrobial hand soaps in vitro and in vivo. J Hosp Infect 2012; 82: 277-80
195. Liu P, Yuen Y, Hsiao HM, et al. Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands. Appl Environ Microbiol 2010; 76: 394-9
196. Horvath LL, Murray CK, Dooley DP. Effect of maximizing a travel medicine clinic?s prevention strategies. J Travel Med 2005; 12: 332-7
197. Luby SP, Agboatwalla M, Painter J, et al. Combining drinking water treatment and hand washing for diarrhoea prevention, a cluster randomised controlled trial. Trop Med Int Health 2006; 11: 479-89
198. Luby SP, Agboatwalla M, Painter J, et al. Effect of intensive handwashing promotion on childhood diarrhea in high-risk communities in Pakistan: a randomized controlled trial. JAMA 2004; 291: 2547-54
199. Kamm KB, Feikin DR, Bigogo GM, et al. Associations between presence of handwashing stations and soap in the home and diarrhoea and respiratory illness, in children less than fi ve years old in rural western Kenya. Trop Med Int Health 2014; 19: 398-406
200. Hubner NO, Hubner C, Wodny M, et al. Effectiveness of alcohol-based hand disinfectants in a public administration: impact on health and work performance related to acute respiratory symptoms and diarrhoea. BMC Infect Dis 2010; 10: 250
201. Boulware DR. Influence of hygiene on gastrointestinal illness among wilderness backpackers. J Travel Med 2004; 11: 27-33
202. Heywood AE, Zhang M, MacIntyre CR, et al. Travel risk behaviours and uptake of pre-travel health preventions by university students in Australia. BMC Infect Dis 2012; 12: 43
203. Yanni EA, Marano N, Han P, et al. Knowledge, attitudes, and practices of US travelers to Asia regarding seasonal infl uenza and H5N1 avian infl uenza prevention measures. J Travel Med 2010; 17: 374-81
204. Namikawa K, Iida T, Ouchi K, et al. Knowledge, attitudes, and practices of Japanese travelers on infectious disease risks and immunization uptake. J Travel Med 2010; 17: 171-5
205. Hartjes LB, Baumann LC, Henriques JB. Travel health risk perceptions and prevention behaviors of US study abroad students. J Travel Med 2009; 16: 338-43
206. Steffen R, Connor BA. Vaccines in travel health: from risk assessment to priorities. J Travel Med 2005; 12: 26-35
207. DuPont HL, Ericsson CD, Johnson PC, et al. Prevention of travelers? Diarrhea by the tablet formulation of bismuth subsalicylate. Jama 1987; 257: 1347-50
208. DuPont HL, Sullivan P, Evans DG, et al. Prevention of traveler?s diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth). JAMA 1980; 243: 237-41
209. Steffen R, DuPont HL, Heusser R, et al. Prevention of traveler?s diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agents Chemother 1986; 29: 625-7
210. Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli -induced diarrhea in volunteers. Gastroenterology 1983; 85: 1017-22
211. Manhart MD. In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts. Rev Infect Dis 1990; 12: Suppl 1 S11-S15
212. Ward RL, Sander DS, Knowlton DR. I n vitro activities of bismuth salts against rotaviruses and other enteric viruses. Antimicrob Agents Chemother 1985; 27: 306-8
213. Bagchi D, McGinn TR, Ye X, et al. Mechanism of gastroprotection by bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells. Dig Dis Sci 1999; 44: 2419-28
214. Copeman M, Matuz J, Leonard AJ, et al. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the Effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J Gastroenterol Hepatol 1994; 9: Suppl 1 S55-S59
215. DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for prevention of travelers? Diarrhea. J Travel Med 2009; 16: 149-60
216. Mendelowitz PC, Hoffman RS, Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Ann Intern Med 1990; 112: 140-1
217. Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006; 6: 374-82
218. McFarland LV. Meta-analysis of probiotics for the prevention of traveler?s diarrhea. Travel Med Infect Dis 2007; 5: 97-105
219. Kollaritsch H, Wiedermann G. Prevention of Traveler?s Diarrhea: A Double-Blind Randomized Trial with Saccharomyces cerevisiae Hansen CBS 5926. In: Steffen R, et al. (eds). Proceedings of the First Conference on International Travel Medicine, Zürich, Switzerland, 5-8 April 1988. Berlin: Springer-Verlag, 1989, pp 328-56
220. Kollaritsch H, Holst H, Grobara P, et al. Prevention of travelers? Diarrhea with Saccharomyces boulardii: results of a placebo controlled double-blind study. Fortschr Med 1993; 111: 152-6
221. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers? Diarrhoea by Lactobacillus GG. Ann Med 1990; 22: 53-6
222. Hilton E, Kolakowski P, Singer C, et al. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med 1997; 4: 41-3
223. De dios Pozo-Olano J, Warram JJ, Gomez R, et al. Effect of Lactobacilli preparation on travelers? Diarrhea. Gastroenterology 1978; 74: 829-30
224. Katelaris PH, Salam I, Farthing MJ. Lactobacilli to prevent traveler?s diarrhea? N Engl J Med 1995; 333: 1360-1
225. Drakoularakou A, Tzortzis G, Rastall RA, et al. A double-blind, placebocontrolled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers? Diarrhoea. Eur J Clin Nutr 2010; 64: 146-52
226. Virk A, Mandrekar J, Berbari EF, et al. A randomized, double blind, placebo-controlled trial of an oral synbiotic (AKSB) for prevention of travelers? Diarrhea. J Travel Med 2013; 20: 88-94
227. Briand V, Buffet P, Genty S, et al. Absence of Efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler?s diarrhea: a randomized, double-blind, controlled study. Clin Infect Dis 2006; 43: 1170-5
228. Levine MM, Hornick RB. Lactulose therapy in Shigella carrier state and acute dysentery. Antimicrob Agents Chemother 1975; 8: 581-4
229. Krokowicz L, Kaczmarek BF, Krokowicz P, et al. Sodium butyrate and short chain fatty acids in prevention of travellers? Diarrhoea: a randomized prospective study. Travel Med Infect Dis 2014; 12: 183-8
230. Tzortzis G. Development and functional properties of Bimuno: a secondgeneration prebiotic mixture. Food Sci Technol Bull 2010; 6: 81-9
231. National Institutes of Health. NIH Consensus Development Conference. Travelers? Diarrhea. JAMA 1985; 253: 2700-4
232. Reves RR, Johnson PC, Ericsson CD, et al. A cost-Effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers? Diarrhea. Arch Intern Med 1988; 148: 2421-7
233. Thomson MA, Booth IW. Treatment of traveller?s diarrhoea. Economic aspects. Pharmacoeconomics 1996; 9: 382-91
234. DuPont HL. New insights and directions in travelers? Diarrhea. Gastroenterol Clin N Am 2006; 35: 337-53. viii-ix
235. Gorbach SL. How to hit the runs for fifty million travelers at risk. Ann Intern Med 2005; 142: 861-2
236. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1499-539
237. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - A meta-analysis. Am J Gastroenterol 2006; 101: 1894-9. quiz 1942
238. Thabane M, Kottachchi DT, Marshall JK. Systematic review and metaanalysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-44
239. Schwille-Kiuntke J, Mazurak N, Enck P. Systematic review with metaanalysis: post-infectious irritable bowel syndrome after travellers? Diarrhoea. Aliment Pharmacol Ther 2015; 41: 1029-37
240. Alajbegovic S, Sanders JW, Atherly DE, et al. Effectiveness of rifaximin and fl uoroquinolones in preventing travelers? Diarrhea (TD): a systematic review and meta-analysis. Syst Rev 2012; 1: 39
241. DuPont HL, Jiang ZD, Okhuysen PC, et al. Antibacterial chemoprophylaxis in the prevention of traveler?s diarrhea: evaluation of poorly absorbed oral rifaximin. Clin Infect Dis 2005; 41 Suppl 8: S571-S576
242. Armstrong AW, Ulukan S, Weiner M, et al. A randomized, double-blind, placebo-controlled study evaluating the Efficacy and safety of rifaximin for the prevention of travelers? Diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. J Travel Med 2010; 17: 392-4
243. Flores J, Dupont HL, Jiang ZD, et al. A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers? Diarrhea in Mexico during the dry season. J Travel Med 2011; 18: 333-6
244. Zanger P, Nurjadi D, Gabor J, et al. Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis 2013; 13: 946-54
245. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006; 42: 1283-8
246. Batz MB, Henke E, Kowalcyk B. Long-term consequences of foodborne infections. Infect Dis Clin N Am 2013; 27: 599-616
247. Pandey P, Bodhidatta L, Lewis M, et al. Travelers? Diarrhea in Nepal: an update on the pathogens and antibiotic resistance. J Travel Med 2011; 18: 102-8
248. Vlieghe ER, Jacobs JA, Van Esbroeck M, et al. Trends of norfl oxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006. J Travel Med 2008; 15: 419-25